CTLT: Catalent, Inc.
About
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
Current Value
$58.721 Year Return
Current Value
$58.721 Year Return
Key Details
Market Cap
$10.69B
P/E Ratio
-25.94
1Y Stock Return
47.79%
1Y Revenue Growth
4.39%
Dividend Yield
0.00%
Price to Book
3.0
Strategies that include CTLT
Stock's related to CTLT
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MSFT | 0.01% | $3.11T | +11.99% | 0.54% |
| TH | -0.01% | $839.02M | -24.49% | 0.00% |
| XOS | -0.06% | $30.51M | -57.24% | 0.00% |
| XYL | -0.11% | $29.70B | +21.00% | 1.15% |
| HURN | -0.12% | $2.13B | +14.70% | 0.00% |
| LTM | -0.14% | $8.51B | -100.00% | <0.01% |
| OTTR | -0.17% | $3.35B | +6.14% | 2.35% |
| IMNN | -0.17% | $10.02M | -22.89% | 0.00% |
| ALTM | -0.21% | $5.58B | -23.79% | 0.00% |
| TMUS | 0.26% | $270.63B | +56.92% | 0.83% |
| WLKP | -0.28% | $796.39M | +4.00% | 8.34% |
| AON | 0.28% | $82.00B | +16.33% | 0.70% |
| FCN | -0.30% | $7.10B | -10.74% | 0.00% |
| CYD | 0.34% | $364.46M | -2.94% | 4.26% |
| HSY | 0.37% | $34.45B | -10.68% | 3.21% |
| CORT | 0.38% | $5.69B | +113.63% | 0.00% |
| RTX | 0.39% | $158.34B | +52.22% | 2.09% |
| CMTL | 0.39% | $84.44M | -76.16% | 0.00% |
| DXCM | -0.42% | $29.25B | -31.28% | 0.00% |
| UTI | -0.44% | $1.07B | +73.54% | 0.00% |
ETF's related to CTLT
News
SeekingAlpha
BlackRock Event Driven Equity Fund The Fund was up over the quarter with hard catalyst, soft catalyst, and credit investments all contributing to returns.
SeekingAlpha
Navigating M&A stocks has been challenging this year due to regulatory blocks, financing issues, and buyer remorse. Click here for a detailed analysis.
Yahoo
We came across a bullish thesis on Avid Bioservices, Inc. (CDMO) on Twitter by northeasternsvf. In this article, we will summarize the bulls’ thesis on CDMO. Avid Bioservices, Inc. (CDMO)’s share was trading at $12.20 as of Nov 13th. CDMO’s trailing and forward P/E were 9.41 and 88.50 respectively according to Yahoo Finance. Avid Bioservices, Inc., a […]
Yahoo
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent, people familiar with the matter said. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss drug Wegovy propelled it to become Europe's most valuable company by market value. While the questionnaire shows the European Commission seeking to understand the market, it could allow rivals and customers to flag potential anti-competitive concerns.
Yahoo
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
SeekingAlpha
Greenhaven Road Capital Fund returned approximately +15% net during the third quarter, bringing year-to-date returns to approximately +12% net. Read more here.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.